Sarepta Therapeutics, Inc.

Historical 13F Holders

Symbol
SRPT
CUSIP
803607100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 803607100 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 15.8% 7/30/2026
Event 6/30/2026
State Street Corp 13G
8.4% 8/7/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G/A 8.1% 7/31/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
AQR Capital Management, LLC 13G/A
5.1% 8/13/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
D. E. Shaw & Co., L.P. 13G/A
1.9% 11/14/2025
Event 9/30/2025
Capital International Investors 13G/A 0.5% 8/13/2025
Event 6/30/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 9 5.68 k $104 k
2026 Q2 351 110 M $2.06 B
2026 Q1 377 103 M $2.24 B
2025 Q4 396 93.9 M $2.02 B
2025 Q3 374 87.5 M $1.69 B
2025 Q2 433 87.8 M $1.50 B
2025 Q1 479 88.3 M $5.58 B
2024 Q4 514 89.3 M $10.7 B
2024 Q3 511 90.6 M $11.1 B
2024 Q2 547 93.5 M $14.8 B
2024 Q1 464 87.0 M $11.3 B
2023 Q4 451 84.9 M $8.20 B
2023 Q3 462 83.6 M $10.1 B
2023 Q2 454 82.3 M $9.43 B
2023 Q1 477 81.8 M $11.3 B
2022 Q4 460 82.0 M $10.6 B
2022 Q3 419 84.9 M $9.38 B
2022 Q2 369 73.5 M $5.51 B
2022 Q1 362 73.3 M $5.73 B
2021 Q4 393 72.3 M $6.51 B
2021 Q3 346 65.8 M $6.08 B
2021 Q2 367 65.0 M $5.05 B
2021 Q1 406 66.6 M $4.97 B
2020 Q4 526 72.2 M $12.3 B
2020 Q3 464 72.3 M $10.1 B
2020 Q2 459 74.2 M $11.9 B
2020 Q1 418 74.8 M $7.31 B
2019 Q4 446 74.5 M $9.61 B
2019 Q3 397 75.4 M $5.63 B
2019 Q2 431 73.3 M $11.1 B
2019 Q1 421 71.3 M $8.51 B
2018 Q4 382 69.4 M $7.58 B
2018 Q3 390 63.0 M $10.2 B
2018 Q2 362 60.9 M $8.05 B
2018 Q1 303 57.8 M $4.28 B
2017 Q4 296 55.3 M $3.07 B
2017 Q3 284 53.7 M $2.44 B
2017 Q2 225 42.7 M $1.44 B
2017 Q1 215 41.0 M $1.21 B
2016 Q4 227 39.8 M $1.09 B
2016 Q3 248 42.4 M $2.61 B
2016 Q2 206 34.6 M $661 M
2016 Q1 166 35.1 M $686 M
2015 Q4 191 28.6 M $1.10 B
2015 Q3 175 30.6 M $982 M
2015 Q2 154 26.7 M $812 M
2015 Q1 128 24.2 M $321 M
2014 Q4 145 25.0 M $363 M
2014 Q3 145 26.0 M $549 M
2014 Q2 148 29.9 M $892 M
2014 Q1 139 26.6 M $639 M